Skip to main content
. 2009 Feb 2;119(3):565–572. doi: 10.1172/JCI37865

Figure 2. Anti–IFN-γ treatment inhibits activation of CD11b+ cells but not the effect on diabetes by anti–IL-17A administration.

Figure 2

(A) Histogram of MHC class II expression (left panel) on CD11b-expressing cells isolated from the pancreata of isotype- (thick line) or anti–IFN-γ–treated (thin line) NOD/SCID recipients, and MFI of MHC class II on individual samples (right panel). Horizontal bars represent mean MHC class II MFI, and individual points represent MHC class II MFI of CD11b-infiltrating cells from individual mice. (B) mRNA expression of iNOS and programmed death ligand 1 (PD-L1) is shown. Mean ± SEM. (C) Th17 and Th1 BDC2.5 T cells were adoptively transferred into antibody-treated NOD/SCID recipients. Th1 was transferred into isotype control–treated (open triangles) or anti–IL-17A–treated (filled diamonds) hosts. Th17 was transferred into isotype-treated (open diamonds) or anti–IL-17A–treated (filled squares) hosts. Mice were injected with 2 mg of isotype (OX-1) or anti–IL-17A (MM17-F3) on days 0, 2, 4, and 6. n = 5.